John Tisdale

MD. Director, Cellular and Molecular Therapeutics Branch, NHLBI · Clinical Center at the National Institutes of Health

Credentials: · ·

History

Cellular and Molecular Therapeutics Branch · Clinical Center at the National Institutes of Health
Present

Resource for the Development of Biomedical Accelerator Mass Spectrometry (AMS)
National Center for Research Resources · P41
Project lead · $46.8K · University of Calif-Lawrnc Lvrmr Nat Lab
2011–2012
Nonmyeloablative Allogeneic PBSC in Globin Disorders
National Heart, Lung, and Blood Institute · ZIA
Contact PI · $18.4M · National Heart, Lung, and Blood Institute
Preclinical and Clinical Studies in Gene Therapy for Sickle Cell Disease
National Heart, Lung, and Blood Institute · ZIA
Contact PI · $14.6M · National Heart, Lung, and Blood Institute
Isolation, Characterization, and Transplantation of Candidate Stem Cells
National Heart, Lung, and Blood Institute · ZIA
Contact PI · $13.5M · National Heart, Lung, and Blood Institute

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
Principal investigator · Recruiting · Phase 1, Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
2026–2035
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Principal investigator · Recruiting · Early phase 1
National Heart, Lung, and Blood Institute (NHLBI)
2024–2029
Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Heart, Lung, and Blood Institute (NHLBI)
2022–2027
Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
Principal investigator · Completed · Early phase 1
National Heart, Lung, and Blood Institute (NHLBI)
2021–2023